Researchers from the Oncological, Translational, Epidemiological and Clinical Research Group (GIOTEC), the Pere Virgili Health Research Institute (IISPV) and the Sant Joan University Hospital in Reus, have recruited the first patient for this phase II trial, in which 9 hospitals throughout Spain are participating and which aims to test the efficacy of the drug Niraparib to treat women who have suffered from ovarian cancer and who have relapsed in the form of single metastases after previous maintenance therapy with a drug from the same family as Niraparib.
The medication that will be tested in this clinical trial will be administered to treat them once they have been operated on for oligometastases.
30 patients are needed for the ANALLISA clinical trial. The objective of the trial is to confirm above all the efficacy and safety of the drug.
The main researcher of the GIOTEC research group that participates in the trial together with other 8 hospitals in Spain is Dra. Maria Masvidal Hernandez.
Facebook 
Mail 
WhatsApp 
